Orally Dissolving Strip Market Size, Share, Growth, and Industry Analysis, By Types (Orodispersible Film, Oromucosal Film) , Applications (Hospital and Clinic, Drug Store, E-commerce) and Regional Insights and Forecast to 2033

Orally Dissolving Strip Market Size

The global Orally Dissolving Strip market size was valued at USD 662.27 million in 2024 and is projected to reach USD 704.66 million in 2025, expanding to USD 1,157.48 million by 2033. With a CAGR of 6.4% from 2025 to 2033, this market is growing due to rising demand for fast-dissolving drug delivery systems, especially for pediatric and geriatric populations.

The US Orally Dissolving Strip market is expanding due to increasing pharmaceutical investments in innovative drug formulations, coupled with consumer preference for easy-to-administer medications.

The Orally Dissolving Strip (ODS) market is experiencing significant growth, driven by the increasing demand for innovative drug delivery solutions. These strips offer enhanced bioavailability, improved patient compliance, and ease of administration, particularly for pediatric and geriatric populations.

The pharmaceutical segment dominates the market, with over 60% share in applications related to pain relief, allergies, and neurological disorders. Growing consumer preference for convenient and fast-acting drug delivery systems is propelling market expansion. Additionally, the nutraceutical sector holds over 25% share, with rising demand for oral strips infused with vitamins, minerals, and herbal extracts. Advancements in polymer-based formulations are fueling further market penetration.

Orally Dissolving Strip Market Trends

The Orally Dissolving Strip market is witnessing rapid advancements, driven by innovations in polymer science and drug formulation technologies. Currently, over 70% of pharmaceutical companies are investing in ODS technology due to its enhanced drug absorption rates and faster onset of action. The global shift towards on-the-go medication has contributed to a 40% increase in demand for ODS-based treatments over the past five years.

In the nutraceutical sector, oral dissolving strips now account for more than 30% of new product launches in functional supplements. Consumers are actively seeking sugar-free, non-GMO, and vegan-friendly formulations, leading to a 50% surge in herbal and vitamin-infused oral strips. Additionally, smart packaging solutions incorporating QR codes and authentication features have increased by 25%, ensuring product safety and traceability.

The rapid adoption of telemedicine and e-pharmacies has also played a role, with online sales contributing over 35% of the total market share for ODS products. Companies focusing on sublingual drug delivery report a 45% higher acceptance rate among patients with dysphagia. Moreover, research in nanotechnology-based ODS formulations has grown by 55%, promising future breakthroughs in targeted drug delivery.

Orally Dissolving Strip Market Dynamics

DRIVER

" Increasing Preference for Alternative Drug Delivery Systems"

The preference for orally dissolving strips has surged by 60% as patients seek needle-free, easy-to-administer medications. The geriatric population, which constitutes over 15% of the global market demand, is a key driver due to difficulties in swallowing traditional tablets and capsules. Pharmaceutical firms are expanding their ODS product lines, with investments growing by 50% in R&D to enhance formulation efficiency. In addition, the rising demand for instant pain relief solutions has driven a 40% growth in analgesic and anti-inflammatory ODS products.

RESTRAINT

" Limited Drug Load Capacity in Oral Strips"

Despite growing demand, over 35% of potential pharmaceutical formulations are currently unsuitable for ODS due to limited drug load capacity. This restricts their application in high-dose medications. Furthermore, production costs have risen by 25%, making it challenging for small manufacturers to compete. Stability issues also hinder growth, with nearly 30% of ODS products requiring special packaging to prevent moisture degradation. Regulatory approvals remain a hurdle, as over 40% of new ODS formulations face delays due to stringent safety and efficacy requirements.

OPPORTUNITY

" Expansion in Nutraceutical and CBD-Infused Strips"

The nutraceutical sector has witnessed a 50% rise in the adoption of orally dissolving strips, particularly for herbal supplements, vitamins, and probiotics. Additionally, CBD-infused ODS products have gained a 45% market share in regions where cannabis-based products are legal. Growing consumer interest in plant-based, sugar-free, and organic alternatives has led to a 35% rise in functional ODS offerings. As global demand for personalized medicine grows, customized oral strips with precise dosing have seen a 30% increase in clinical research trials, promising future expansion.

CHALLENGE

" High Manufacturing and R&D Costs"

The production costs of ODS products have increased by 40%, primarily due to expensive polymeric materials and advanced formulation requirements. The research and development phase takes 30% longer than conventional tablets, slowing new product launches. Additionally, regulatory compliance costs have surged by 25%, making it difficult for startups and mid-sized players to enter the market. Consumer awareness remains a challenge, as over 35% of potential users are still unfamiliar with ODS benefits. Moreover, the limited availability of advanced manufacturing equipment has slowed production capacity by 20% in certain regions.

Segmentation Analysis 

The Orally Dissolving Strip (ODS) market is segmented based on type and application, offering diverse opportunities across pharmaceutical and nutraceutical industries. The Orodispersible Film segment accounts for nearly 70% of the market due to its rapid disintegration and ease of administration, especially for geriatric and pediatric patients. On the other hand, the Oromucosal Film segment holds around 30% market share, driven by increasing demand for localized drug delivery.
In terms of application, the hospital and clinic segment dominates with over 50% share, as healthcare providers prefer ODS for precise dosing. Drug stores contribute around 30%, while the e-commerce segment is growing at 40% due to rising online pharmacy trends.

By Type

• Orodispersible Film: The Orodispersible Film (ODF) segment commands nearly 70% of the market share, largely due to its fast dissolution within 5-10 seconds and high patient preference. These films are widely used for neurological disorders, pain management, and allergy relief. More than 60% of pharmaceutical companies are focusing on ODF formulations to improve patient compliance. Pediatric and geriatric populations drive over 55% of demand, as these strips eliminate swallowing difficulties. Additionally, over 40% of recent FDA approvals for oral strips are in the ODF category, indicating strong growth potential in this segment.
• Oromucosal Film: The Oromucosal Film segment holds approximately 30% of the ODS market, mainly due to its targeted drug delivery benefits. These films are often used for opioid dependence treatment, hormone therapy, and pain management. In the oncology sector, over 35% of new drug formulations are being developed in Oromucosal Film form due to their efficient absorption. Additionally, sublingual and buccal drug delivery methods are gaining traction, leading to a 45% increase in demand for Oromucosal Films in specialized therapies. Manufacturers are investing 30% more in R&D to develop next-generation oromucosal strips with enhanced bioavailability.

By Application

• Hospital and Clinic: The hospital and clinic segment accounts for over 50% of the total Orally Dissolving Strip market due to the preference for precise dosing and fast-acting drug delivery. ODS is increasingly used in emergency treatments, where rapid absorption is critical, especially for pain relief and anti-nausea medications. Additionally, over 40% of ODS-based prescriptions are written in hospitals for pediatric and geriatric patients. With rising hospital admissions by 20% annually, the demand for oral strips is growing in therapeutic areas like cardiology, neurology, and gastrointestinal disorders.
• Drug Store: Traditional drug stores contribute around 30% of ODS sales, as consumers continue to prefer purchasing medications through offline channels. Nearly 65% of OTC oral strips are sold through pharmacies, particularly for cold relief, allergy treatments, and dietary supplements. Moreover, the availability of private-label ODS brands has increased by 35%, making them more accessible at retail chains. Pharmacies also report a 25% rise in demand for CBD-infused and herbal oral strips, indicating a shift towards alternative health solutions.
• E-Commerce: The e-commerce segment is witnessing rapid growth, accounting for nearly 40% of total ODS sales. Online pharmacies and digital health platforms have seen a 50% surge in demand for ODS products, driven by increasing consumer preference for home delivery. Over 30% of online purchases include nutraceutical strips, reflecting growing interest in functional wellness products. Additionally, pharmaceutical brands report a 20% increase in direct-to-consumer sales, leveraging online platforms for targeted marketing. The rise of subscription-based medication services has also fueled a 25% uptick in ODS orders via digital channels.



Request a Free sample    to learn more about this report.

Orally Dissolving Strip Regional Outlook

The Orally Dissolving Strip market is expanding globally, with North America holding over 40% share, driven by strong pharmaceutical R&D. Europe accounts for nearly 30%, with increasing adoption of OTC oral strips. The Asia-Pacific region is growing at the fastest rate, with a 50% surge in demand for nutraceutical ODS products. The Middle East & Africa region holds around 10%, supported by expanding healthcare access and rising awareness of ODS benefits. The market is evolving rapidly due to increasing investments, regulatory approvals, and advancements in film-based drug formulations.

North America 

North America dominates the market with over 40% share, led by the United States, which accounts for more than 75% of regional demand. The FDA has approved over 50% of global ODS formulations, fostering a robust product pipeline. Nearly 60% of pharmaceutical companies in the region are investing in ODS-based drug development. Additionally, over 55% of U.S. consumers prefer fast-dissolving medications due to convenience. The CBD-infused ODS segment has grown by 45%, driven by increasing legalization and consumer interest. The region also sees a 30% rise in telemedicine prescriptions, boosting online ODS sales.

Europe

Europe accounts for approximately 30% of the global ODS market, with Germany, the UK, and France contributing over 70% of regional sales. The nutraceutical segment is growing rapidly, with a 40% rise in demand for vitamin and herbal-infused strips. Nearly 35% of European consumers prefer sugar-free and vegan-friendly ODS options, driving innovation. Additionally, over 25% of new pharmaceutical oral strips launched in Europe are focused on pain relief and mental health treatments. Regulatory approvals in the EU have increased by 20%, enabling faster product launches. Online sales of ODS in Europe have surged by 30% year-on-year.

Asia-Pacific

Asia-Pacific is the fastest-growing market, with a 50% increase in consumer demand for ODS products. India and China together contribute over 60% of the regional market share, driven by rising healthcare investments and expanding pharmaceutical industries. The nutraceutical ODS segment has seen a 55% surge, as consumers increasingly prefer herbal-based oral strips. Additionally, government initiatives promoting fast-dissolving drug formulations have led to a 40% increase in pharmaceutical R&D investments. E-commerce sales are booming, with over 35% of ODS purchases made online. The region is also experiencing a 30% rise in OTC oral strip sales, fueled by urbanization.

Middle East & Africa 

The Middle East & Africa (MEA) region holds around 10% of the global ODS market, with Saudi Arabia, the UAE, and South Africa being key contributors. The pharmaceutical ODS sector has expanded by 35%, supported by increased healthcare funding. Additionally, over 30% of MEA consumers are opting for herbal and halal-certified oral strips, boosting demand in nutraceuticals. Online sales have risen by 25%, driven by improved internet penetration and digital pharmacies. Government-led healthcare initiatives have increased ODS adoption in hospitals by 20%. However, limited manufacturing infrastructure remains a challenge, leading to a 30% dependency on imports.

LIST OF KEY ORALLY DISSOLVING STRIP MARKET COMPANIES PROFILED

• Aquestive Therapeutics
• Kyukyu Pharmaceutical
• BioDelivery (BDSI)
• IntelGenx
• Tapemark
• Shilpa Therapeutics
• CL Pharm
• Lubrizol Life Science
• Adhex Pharma
• DK Livkon
• Arx Pharma
• Aavishkar
• ZIM Laboratories
• Umang Pharmaceuticals
• Cure Pharmaceutical

Top 2 Companies with Highest Market Share

• Aquestive Therapeutics - Holds approximately 25% of the global market share, leading in FDA-approved ODS drug formulations. The company specializes in prescription-based oral strips, with over 50% of its product portfolio focused on neurological and opioid dependence treatments.
• BioDelivery (BDSI) - Captures nearly 20% of the ODS market, focusing on pain management and oncology ODS formulations. The company has reported a 35% increase in prescription ODS sales over the last three years.

Investment Analysis and Opportunities 

The Orally Dissolving Strip (ODS) market is attracting significant investments due to its high patient compliance rate, rapid drug absorption, and expanding applications in both pharmaceuticals and nutraceuticals. In 2023 alone, global investments in ODS research and development increased by 45%, driven by pharmaceutical companies aiming to enhance drug bioavailability. Additionally, over 60% of leading pharmaceutical firms have expanded their ODS product lines, with investments directed toward sublingual drug delivery and personalized medicine.

The nutraceutical sector has seen a 50% rise in funding, particularly for herbal-infused, CBD-based, and vitamin-rich oral strips. Governments and regulatory bodies are supporting the growth of ODS technology, with over 35% of new drug approval applications in 2023 focusing on ODS formulations. Investments in smart packaging, which grew by 30% last year, are also helping to ensure product stability and traceability.

Additionally, pharma tech startups focusing on film-based drug delivery have secured a 40% increase in venture capital funding, demonstrating strong market potential. Emerging markets like India and China have experienced a 55% increase in ODS manufacturing investments, highlighting significant opportunities for expansion. The rising demand for fast-acting, non-invasive medications is expected to sustain this investment growth trajectory.

New Product Development 

In 2023 and 2024, over 70 new orally dissolving strip products have been introduced across pharmaceutical and nutraceutical applications. The pharmaceutical industry has focused on neurological treatments, pain management, and allergy relief, with over 40% of new launches targeting these segments. Recent developments in opioid dependence therapy have resulted in a 35% increase in sublingual strip formulations, providing a more efficient alternative to traditional tablets.

In the nutraceutical segment, vitamin-infused and herbal oral strips have seen a 50% growth in new product introductions, with many brands launching sugar-free, non-GMO, and vegan-friendly variants. Additionally, the CBD-infused oral strips market has expanded by 45%, catering to consumers looking for alternative wellness solutions.

One of the biggest advancements has been the development of nano-film ODS, which enhances drug solubility and absorption by over 60% compared to traditional strips. Several pharmaceutical companies have introduced dual-layer oral strips, allowing for controlled drug release and improved efficacy. Furthermore, over 30% of new products include temperature-resistant formulations, ensuring better stability and extended shelf life. These innovations are driving consumer interest and regulatory approvals, further propelling market growth.

Recent Developments by Manufacturers in the Orally Dissolving Strip Market 

In 2023 and 2024, leading pharmaceutical and nutraceutical companies have focused on expanding their product portfolios, securing regulatory approvals, and adopting advanced formulation technologies. Aquestive Therapeutics launched a new sublingual film for epilepsy treatment, which has been reported to improve drug absorption by 45% compared to traditional tablets. IntelGenx received FDA approval for a migraine treatment ODS, making it one of the top five best-selling dissolvable strips in the U.S. market.

In the nutraceutical industry, ZIM Laboratories introduced a new herbal-based vitamin strip, which has gained 30% market penetration within six months of its launch. Kyukyu Pharmaceutical expanded its production capacity by 40%, investing in new polymer-based film technologies to enhance drug solubility.

Manufacturers are also focusing on sustainable and biodegradable ODS materials, with over 25% of new product lines using eco-friendly polymers. Additionally, the number of partnerships between pharmaceutical firms and biotechnology startups has risen by 35%, accelerating innovation. E-commerce sales of ODS products have increased by 50%, with major manufacturers launching direct-to-consumer platforms to improve accessibility. These advancements demonstrate strong growth potential for ODS technology across various medical and wellness applications.

REPORT COVERAGE of the Orally Dissolving Strip Market 

The Orally Dissolving Strip (ODS) Market Report provides a comprehensive analysis of market trends, competitive landscape, segmentation, investment opportunities, and new product developments. Covering 2023 and 2024, the report highlights major industry players, key innovations, and market expansion strategies.

The market segmentation section details the dominance of Orodispersible Films, which account for 70% of total ODS demand, and the rapid growth of Oromucosal Films, which hold 30% of the market share. The application analysis covers the increasing adoption of ODS in hospitals (50% market share), drug stores (30%), and e-commerce (40%).

The regional outlook highlights North America as the leading market, holding over 40% of global sales, followed by Europe (30%), Asia-Pacific (fastest-growing, with 50% demand surge), and the Middle East & Africa (10% market share).

Additionally, the report includes insights into recent developments, with 70+ new ODS products launched in the past two years and a 45% increase in ODS-related R&D investments. Investment analysis highlights the 40% surge in venture capital funding for ODS startups and the 30% rise in regulatory approvals for ODS formulations.

This report serves as a valuable resource for investors, manufacturers, and healthcare providers looking to capitalize on the growing demand for fast-acting, patient-friendly drug delivery solutions.